Related Experiment Video
Updated: May 26, 2026
05:31
Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
-765 G→C and -1195 A→G promoter variants of the cyclooxygenase-2 gene decrease the risk for preeclampsia
Figen Gurdol1, Bedia Cakmakoglu, Selcuk Dasdemir
1Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. figur@istanbul.edu.tr
Genetic Testing and Molecular Biomarkers
|January 10, 2012
Summary
Single nucleotide polymorphisms in the cyclooxygenase-2 (COX-2) gene promoter region are linked to preeclampsia risk. Specific COX-2 gene variants may influence preeclampsia onset by affecting gene expression.
Area of Science:
- Genetics
- Obstetrics
- Molecular Biology
Background:
- Cyclooxygenase-2 (COX-2) mediates inflammation by producing prostaglandins.
- Previous studies on COX levels in preeclampsia placentas yielded conflicting results.
- Investigating genetic variations in COX-2 is crucial for understanding preeclampsia etiology.
Purpose of the Study:
- To determine if single nucleotide polymorphisms (SNPs) in the COX-2 gene promoter are associated with preeclampsia.
- To analyze the association between specific COX-2 gene polymorphisms and preeclampsia risk.
Main Methods:
- Polymerase chain reaction and restriction fragment length polymorphism were used.
- Genotyping was performed on 128 controls and 74 preeclamptic patients.
- Two promoter region polymorphisms (-765G→C and -1195 A→G) of the COX-2 gene were examined.
Main Results:
- Significant differences in genotype distribution and allelic frequencies for the -765G→C polymorphism were observed between preeclamptic patients and controls.
- The -765G allele showed an odds ratio (OR) of 4.07 for preeclampsia risk.
- The AA genotype of the -1195 A→G variant was significantly more frequent in preeclamptic subjects (OR: 3.44).
- Moderate linkage was found between the -765G and -1195A variants.
Conclusions:
- SNPs in the COX-2 gene promoter, specifically -765G→C and -1195 A→G, may be associated with preeclampsia.
- These genetic variations might influence preeclampsia risk by altering COX-2 gene expression rates.
- Further research is warranted to elucidate the precise role of these COX-2 SNPs in preeclampsia pathogenesis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...